Completed PHASE3 INTERVENTIONAL NCT00266669

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

Phase III in-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon

Sponsor: MediQuest Therapeutics

Conditions Raynaud's Disease

Interventions Topical organogel with nitroglycerin

Updated 6 times since 2017 Last updated: Aug 6, 2007 Started: Dec 31, 2005 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00266669, this PHASE3 trial focuses on Raynaud's Disease and remains completed. Sponsored by MediQuest Therapeutics, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MediQuest Therapeutics

Data source: MediQuest Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Baltimore, United States , Boston, United States , Charleston, United States , Chicago, United States , Denver, United States , Durham, United States , East Setauket, United States , Farmington, United States , Grand Rapids, United States and 9 more locations